Cargando…
New onset severe ulcerative colitis following Ixekizumab therapy
Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
UMF “Gr. T. Popa” Iasi Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/ https://www.ncbi.nlm.nih.gov/pubmed/36628163 http://dx.doi.org/10.22551/2022.37.0904.10227 |
_version_ | 1784854308739612672 |
---|---|
author | Morosanu, Alina Mihaela Mihai, Ioana Ruxandra Rezus, Ioana Irina Gavrilescu, Otilia Dranga, Mihaela Prelipcean, Cristina Cijevschi Mihai, Catalina |
author_facet | Morosanu, Alina Mihaela Mihai, Ioana Ruxandra Rezus, Ioana Irina Gavrilescu, Otilia Dranga, Mihaela Prelipcean, Cristina Cijevschi Mihai, Catalina |
author_sort | Morosanu, Alina Mihaela |
collection | PubMed |
description | Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease. |
format | Online Article Text |
id | pubmed-9769074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | UMF “Gr. T. Popa” Iasi Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-97690742023-01-09 New onset severe ulcerative colitis following Ixekizumab therapy Morosanu, Alina Mihaela Mihai, Ioana Ruxandra Rezus, Ioana Irina Gavrilescu, Otilia Dranga, Mihaela Prelipcean, Cristina Cijevschi Mihai, Catalina Arch Clin Cases Case Report Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease. UMF “Gr. T. Popa” Iasi Publishing House 2022-12-19 /pmc/articles/PMC9769074/ /pubmed/36628163 http://dx.doi.org/10.22551/2022.37.0904.10227 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Morosanu, Alina Mihaela Mihai, Ioana Ruxandra Rezus, Ioana Irina Gavrilescu, Otilia Dranga, Mihaela Prelipcean, Cristina Cijevschi Mihai, Catalina New onset severe ulcerative colitis following Ixekizumab therapy |
title | New onset severe ulcerative colitis following Ixekizumab therapy |
title_full | New onset severe ulcerative colitis following Ixekizumab therapy |
title_fullStr | New onset severe ulcerative colitis following Ixekizumab therapy |
title_full_unstemmed | New onset severe ulcerative colitis following Ixekizumab therapy |
title_short | New onset severe ulcerative colitis following Ixekizumab therapy |
title_sort | new onset severe ulcerative colitis following ixekizumab therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/ https://www.ncbi.nlm.nih.gov/pubmed/36628163 http://dx.doi.org/10.22551/2022.37.0904.10227 |
work_keys_str_mv | AT morosanualinamihaela newonsetsevereulcerativecolitisfollowingixekizumabtherapy AT mihaiioanaruxandra newonsetsevereulcerativecolitisfollowingixekizumabtherapy AT rezusioanairina newonsetsevereulcerativecolitisfollowingixekizumabtherapy AT gavrilescuotilia newonsetsevereulcerativecolitisfollowingixekizumabtherapy AT drangamihaela newonsetsevereulcerativecolitisfollowingixekizumabtherapy AT prelipceancristinacijevschi newonsetsevereulcerativecolitisfollowingixekizumabtherapy AT mihaicatalina newonsetsevereulcerativecolitisfollowingixekizumabtherapy |